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Summary Between October 1977 and December 1983, 379 consecutive patients have been treated for
unilateral, non-metastatic breast cancer, either with conservative (n = 205) or radical surgery (n = 174), with
axillary dissection in all the cases. None of them had histologically proved lymph node involvement. Oestrogen
receptor (ER) and progesterone receptor (PR) levels were measured on each tumour. Levels > 5 fmol mg-'
cytosolic protein were considered as positive for both ER and PR. At 5 years, overall survival (OS) and
disease-free survival (DFS) are respectively 88% and 78%. Unifactorial analysis using Kaplan and Meier
estimates and the log rank test revealed that OS was significantly related to age (P<0.05), tumour size
(P<0.001), histological grading (SBR) (P<0.01), ER (P<0.01) and PR (P<0.001). DFS was significantly
related to the same factors. Menopausal status, number of breast tumour foci and previous familial history of
breast cancer were not significant. Multifactorial analysis revealed that DFS was significantly related to age
(bad prognosis (b.p.) < 37 years old), tumour size and histological grading (b.p. SBR = 3), and that OS was
significantly related to tumour size and PR (b.p. PR < 5 fmol mg-' protein). A prognostic score has been
constructed for both DFS and OS. These scores divide our patients into three significantly different
(P<0.0001) groups with good, intermediate and bad prognosis.
Breast cancer is the most common cause of death from
cancer in women. Prognosis is related to different factors
including lymph node involvement, hence the better prog-
nosis usually attributed to breast cancer with histologically
negative lymph node involvement (N-). For these cancers,
however, overall survival and disease-free survival at 5 years
range respectively from 73 to 90% and from 60 to 90%
(Albano et al., 1979; Bluming et al., 1986; Enquete Per-
manente Cancer, 1982; Fisher et al., 1969, 1983; Henderson,
1987; Nemoto et al., 1980; Sears et al., 1982; Veronesi et al.,
1981). During follow-up, 2-3% N- patients relapse each
year (Bulbrook, 1983). A better knowledge of the factors
linked with a bad prognosis would help to isolate high risk
sub-groups of N- patients for whom randomised trials may
be used to establish optimal therapy.
The purpose of this retrospective study was to try and
determine such factors indicating a bad prognosis and to
construct a prognostic score based on these prognostic fac-
tors to isolate a sub-group of high risk N- patients.
Patients and methods
Between October 1977 and December 1983, 680 consecutive
patients were treated at the H. Becquerel Cancer Centre in
Rouen for invasive, unilateral, unifocal or multifocal breast
cancer. Patients with intraductal carcinoma only were ex-
cluded from this study. No visceral or bony metastases were
detected on these patients by chest X-ray, bone scintigraphy,
hepatic echography or scintigraphy and blood tests. The first
therapeutic step was always a surgical operation. Axillary
lymph node dissection was performed in every case. An
average of 15 nodes per patients (range 2-35) was analysed.
Three hundred and seventy-nine of these patients had no
histologically proved lymph node involvement and constitute
the basis of this study. The various therapies implemented
are detailed in Table I. The average age of the patients at the
date of the initial diagnosis was 56 years (range 29-86
years). The main characteristics of the population are de-
tailed in Table II. Surgery was conservative whenever tech-
nically possible (size of the tumour compared with breast
volume), and this was generally possible for tumours less
than 30 mm in diameter, and when the location of the tu-
mour allowed it, although some central tumours have been
treated with a tumorectomy. When the treatment was conser-
Table I Therapeutic modalities implemented in this study
No adjuvant Adjuvant
Treatment radiotherapy radiotherapy Total
Radical modified mastectomy
+ axillary clearance 111 63 174
Quadrantectomy or tumorectomy
+ axillary clearance 0 205 205
Total 111 268 379
Table II Studied parameters and their repartition
Number of
Studiedparameter patients
Age
< 37 17
38-70 304
>70 58
Previous familial history of breast cancer
Mother II
Sister 16
Mother + sister 3
Menopausal status at initial diagnosis
Non-menopausal 126
Menopausal 253
Clinical size of tumour
TO I
TI 142
T2 227
T3 9
Histological grading
1 69
2 239
3 38
Not performed 33
RO
< 5 fmol mg- 139
> 5 fmol mg-' 240
RP
< Sfmolmg-, 145
> 5 fmol mg-' 234
Number of tumour foci
1 338
>1 41
vative, adjuvant radiotherapy was given using a cobalt-60
source at a dose of 45 Gy to the breast by two opposed
fields. A boost of 15 Gy was delivered in the tumoral zone
with cobalt-60 in six fractions of 2.5 Gy. No radiotherapy
was given on the chest wall if a modified radical mastectomy
had been performed. If the tumour was in the inner quad-
rants, 47.5 Gy adjuvant radiotherapy was given on internal
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mammary lymph nodes and 45 Gy on the supraclavicular
zone. These lymph nodes areas were not irradiated if the
tumour was in the outer quadrants. No patient received
adjuvant hormonotherapy or chemotherapy.
Oestrogen receptor (ER) and progesterone (PR) concentra-
tions were determined in all cases by single saturation meas-
urement on tumour tissue taken before mastectomy using the
dextran coated charcoal method. For both ER and PR, a
value over 5 fmol mg-' cytosol protein (fmol mg-') was con-
sidered as positive (ER+ or PR+) and a value under or
equal to 5fmol mg-' as negative (ER - or PR-).
The number of intramammary tumour foci was determined
by macroscopic examination of the surgical specimen. The
histological grading was determined according to the Bloom
and Richardson method (1957). It could not be specified in
33 cases because of a specific histological subtype: lobular
carcinoma in seven cases, colloid carcinoma in 15 cases and
pure comedocarcinoma in 11 cases. The TNM classification
(UICC, 1978) was used to express the clinical size of tumours
and axillary node status. Menopause was defined as the
permanent cessation of the menses for one year or more.
Clinical follow-up consisted of check-ups at 6-month inter-
vals during the first 5 years, then at 1-year intervals. Max-
imum follow-up time is 110 months and minimum 36 months
(median 60 months).
Statistical methods
Univariate analysis was applied to eight parameters likely to
influence the recurrence of the tumour (Table II). Age of the
patients was divided into the following brackets: <35,
35-40, 41-45 . . 71-75 and >75. Overall survival and
disease free survival were examined for each age bracket.
Because there was no statistical difference between each age
bracket for patients > 37 and < 70, for both disease-free and
overall survival, we decided to match these patients together
and keep only three age-groups: <37, 38-70, >70 years.
The effect of these three age groupings does not disappear
over time. Histological grading was tested in its whole in
both the univariate and multivariate analyses.
Disease-free interval and overall survival (whatever the
cause of death may be) were calculated according to the
actuarial method of Kaplan and Meier (1957). The
significance level of differences between curves (P) was deter-
mined using the log rank test (Mantel, 1966). Percentages
were compared by x2 analysis. Later, those factors with a
prognostic value in the unifactorial analysis were evaluated
using Cox's proportional hazards regression model for cen-
sored data with a stepwise procedure (Cox, 1972) in which
the hazard of recurrence or death for a given patient is the
product of a function of time since mastectomy and a term
describing the effects of the prognostic factors. The regres-
sion coefficients P1, P2 etc. were estimated by maximising the
partial likelihood function after having encoded each prog-
nostic factor tested in the model. A prognostic score (PS) was
calculated for both disease-free and overall survival. The
scores use the P coefficient shown in Table V and the
encoding system described in Table IV. They meet the
general equation: PS = p1.X + P2. Y+ P3.Z + ... where P11, P2
and P3 are the regression coefficients calculated according to
Cox's model and X, Y and Z are the significant prognostic
variables. Prognosis for a given patient is all the worse as the
PS value is high. We then deliberately split these continuous
scores into three groups, according to their distribution his-
togram, and searched for the cut point giving the best disc-
rimination between these groups.
Results
At 2 and 5 years, overall survival rates are respectively
95.2 ± 2% and 88.6 ± 3.7%, whereas disease-free survival
rates are respectively 89.3 ± 3.2% and 77.5 ± 5.0%. Twenty-
three cases of local recurrences, three cases of homolateral
axillary node recurrences and three cases of loco-regional
homolateral recurrences were observed. Two patients devel-
oped contralateral breast cancer. Fifty-two patients devel-
oped metastatic disease. Out of 40 deaths, 29 were due to
cancer evolution. One patient died from an endometrial
cancer diagnosed during a routine follow-up examination.
Unifactorial analysis
The results of univariate analysis on disease-free and overall
survival are reported in Table III. Age <37, tumour size
>5 cm, histological grading SBR 3, oestrogen and/or pro-
gesterone receptors < 5 fmol mg-' are significantly associated
with shorter disease-free or overall survival. Patients aged
between 38 and 70 at first diagnosis have the best chance of
survival and the longest period free of any relapse. Patients
aged <37 at initial diagnosis have the poorest prognosis.
Finally, those aged over 70 show a poor overall survival rate
but a disease-free survival intermediate between the two
groups already mentioned.
Previous familial history of breast cancer, menopausal
status and number of tumor foci do not reach the statistical
level of significance.
Multifactorial analysis
The five factors found to be significant in the unifactorial
analysis plus the factor 'menopausal status' were submitted
to the multivariate analysis (Table IV). The results supplied
by the model for overall survival and disease-free survival are
presented in Table V. Two prognostic parameters are invol-
ved in overall survival prediction: tumour size and pro-
gesterone receptors. Three parameters are involved in dis-
ease-free survival prediction: age at time of initial diagnosis,
tumour size and histological grading.
A prognostic score was calculated both for overall survival
Table III Univariate analysis of prognostic factors: results on disease-free and overall survival
Disease-free survival Overall survival
Studiedparameter (P) (P)
Age <0.01 <0.05
(37-; 38 -70; 70 +) (37- < 70 + < 38-70) (37- < 70 + < 38-70)
Previous familial history n.s. (P = 0.86) n.s. (P = 0.92)
(yes/no)
Menopausal status n.s. (P = 0.50) n.s. (P = 0.17)
Clinical size of tumour < 0.05 < 0.001
(TO, T1, T2, T3) (T3 < T2 < Tl-TO) (T3 < T2 < Ti-TO)
Number of tumour foci n.s. (P = 0.52) n.s. (P = 0.75)
(1; + 1)
Histological grading < 0.001 < 0.01
(1, 2, 3, (n.p.)) (3 < 2, n.p. < 1) (3 < 1, 2, n.p.)
RO <0.05 <0.01 (fmol mg- -5, + 5) (-5 < + 5) (-5 < + 5)
RP < 0.01 < 0.001
(fmol mg' -5, + 5) (-5 < + 5) (-5 < + 5)
n.s., not significant; n.p. not performed438 B. CHEVALLIER et al.
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Table IV Disease-free and overall survival multivariate analysis:
encoding of the tested prognostic factors
Disease-free survival
Agel Oif >37
+ I if < 37
Clinical size of the tumour
- 1 if TO-Ti
0 if T2
+ I if T3
SBR
- 1 if 1
0 if 2 or n.p.
+1 if 3
Menopausal status 0 if pre
+ I if post
Overall survival
Age I 0 if > 37
+ 1 if < 37
Clinical size of the tumour
- if TO-TI
0 if T2
+ 1 if T3
SBR = + I if 1, 2 or n.p.
+ 2 if 3
Age2 Oif >70
+ 1 if > 70
RO
Oif < 5 fmolmg-,
+lif >Sfmolmg-'
RP
Oif <5fmolmg-
+1 if>5fmolmg-'
RO
Oif <5fmolmg'
+lif >5fmolmg'
RP
Oif <5fmolmg-
+1 if > 5 fmolmg'
Age 2 0 if < 70
+ 1 if > 70
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Figure 1 Disease-free survival curves according to prognostic
score. score < -0.58; - - - - -0.57 < score < + 0.65;
...... score > + 0.65.
Menopausal status 0 if pre
+ 1 if post
SBR, histological grading; n.p., not performed; RO, oestrogen
receptors; RP, progesterone receptors.
and for disease-free survival: overall survival,
PS = (1.14 x tumour size) - (1.0 x PR); disease-free survi-
val, PS = (0.91 x age) + (0.27 x tumour size) + (0.850 x his-
tological grading). These scores vary between - 1.12 and
+2.04 (DFS) and -2.14 and + 1.14 (OS) respectively.
Figures I and 2 show the curves for OS and DFS accord-
ing to the prognostic score divided into three groups of
increasing gravity. The differences between the groups are
highly significant (P<0.0001) for both OS and DFS.
Five-year projected disease-free survival rates for the three
groups are respectively 92, 77 and 55%, whereas they are 97,
88 and 77% for projected overall survival. The difference
between these groups is highly significant (P<0.0001).
Discussion
Why do some N - patients have a poor prognosis? A first
explanation may be found in the fact that some of these
patients are not truly N-. The group of patients said to
have no axillary node involvement in actual fact may include
a few women with one or more histologically involved nodes
(Trojani et al., 1987). The accuracy of diagnosis for tumour
involvement versus non-involvement increases with the num-
ber of nodes studied and with the number of sections studied
in a given lymph node (Trojani et al., 1987). With the
immunohistochemical technique using monoclonal anti-
bodies, up to 14% micrometastases can be detected in nodes
diagnosed as not involved using conventional histological
techniques (Trojani et al., 1987). The average number of
nodes studied in our study is high but only standard tech-
niques of histological assay were used on our patients.
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Figure 2 Overall survival curves according to prognostic score.
-____ score < -1.50; ---- -1.50 < score < -0.50; ......
score > -0.50.
Another explanation is that, besides node involvement
status, other factors influence prognosis. Statistical analyses
including multi-parameter regressions are required to isolate
these factors. These analyses give the statistical significance
threshold and prognostic weight of each individual factor by
taking simultaneously into account the weight of the other
factors (Cox, 1972; Locker & Blamey, 1987). Such inform-
ation cannot be obtained from univariate analyses. Few mul-
tifactorial studies on N
- breast cancer have been published
(Bauer et al., 1983; Clark & MacGuire, 1986; Dressler et al.,
1987; Kallioniemi et al., 1987; Parl et al., 1984; Sears et al.,
Table V Results of multivariate analysis on disease-free and overall survival
Disease-free survival Overall survival
Relative Relative
Studiedparameter P P coefficient risk P P coefficient risk
Age < 37 <0.001 + 0.91 2.5 n.s. - -
Clinical size of the tumour <0.005 + 0.27 1.3 <0.01 + 1.14 3.13
Histological grading <0.0003 + 0.85 2.3 n.s. - -
RO n.s. - - n.s. - -
RP n.s. - - <0.004 - 1.0 0.36
Menopausal status n.s. - - n.s.
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1982; Silvestrini et al., 1986; Thorpe et al., 1987; Trojani et
al., 1987; Tubiana et al., 1984). High nuclear grading (Bauer
et al., 1983), high histological grading (Sears et al., 1982;
Stewart et al., 1983; Trojani et al., 1987; Tubiana et al.,
1984), tumour size >5 cm (Clark & MacGuire, 1986; Kal-
lioniemi et al., 1987; Mason et al., 1983; Tubiana et al.,
1984), tumour necrosis (Bauer et al., 1983), macroscopic
invasion of skin by the tumour (Sears et al., 1982), lymph
node hyperplasia (Bauer et al., 1983), negative oestrogen
receptors (Clark & MacGuire, 1986; Mason et al., 1983; Parl
et al., 1984), negative progesterone receptors (Kallioniemi et
al., 1987; Mason et al., 1983) are independent prognostic
factors that may explain N- breast cancer recurrences re-
ported in the literature. Our results are in line with those
already published. In our experience, however, a young age
(< 37) has a high individual prognostic weight. This has been
described for N- breast cancers studied by univariate anal-
ysis only (Adami et al., 1986; Enquete Permanente Cancer,
1982; Host & Lund, 1986).
Age at initial diagnosis, tumour size, histological grading
and progesterone receptor status are probably not the only
variables that can explain a bad prognosis in N- breast
cancers. Shorter disease-free and overall survival have been
reported for patients with N- breast cancers having a high
tritiated thymidine labelling (LI) index (Silvestrini et al.,
1986; Tubiana et al., 1984). The implementation of this
technique is difficult and thus limited to a few centres.
Dressler et al. (1987) have stressed the high relapse rate in
patients with N- breast cancers with mostly aneuploid cells
or with a large fraction in S phase. These two parameters
tested in a multivariate analysis have an independent prog-
nostic weight and seem to offer two different prognostic data.
These results, however, seem to be controversial at the pres-
ent time (Kallioniemi et al., 1987; Muss et al., 1986).
Two factors enabled us to predict shorter overall survival:
negative progesterone receptors and large tumour size. Thus,
positive progesterone receptors seem to supply by themselves
the whole information on the hormonal status of the tumour.
This has already been reported both for N+ (Clark et al.,
1983) and N- breast cancer (Kallioniemi et al., 1987),
although other teams have reported that positive proges-
terone receptors do not add any prognostic information
when ER status is known (Moot et al., 1987).
Three independent prognostic factors are predictive of the
high risk of recurrence in our population: young age, tumour
size >5cm and histological grading 3.
We have constructed a prognostic score both for overall
survival and disease-free survival using the significant factors
selected by the multivariate analysis. According to these
scores, our population is divided into three groups: a high
risk group, a medium risk group and a low risk group. The
predictive value of the scores, however, is relative to the
population studied. It was not possible to validate these
scores, for example with the sample test technique, because
of the relatively small number of patients available for this
test and because of the small number of events observed in
our node negative population. Confirmation would require
the application of these scores by another team to another
population as well as their prospective application.
This study was carried out with a grant from the Departmental
Cancer Committee of Seine Maritime.
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